Iovance Biotherapeutics (FRA:2LB) Shiller PE Ratio: (As of Sep. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2LB Iovance Biotherapeutics Inc FRA:2LB
34 GF Score
Price €6.87
! 3 Warning Signs
View Full Analysis

What is Iovance Biotherapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Iovance Biotherapeutics  (FRA:2LB) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Iovance Biotherapeutics Shiller PE Ratio Related Terms


Iovance Biotherapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Iovance Biotherapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iovance Biotherapeutics Shiller PE Ratio Chart

Iovance Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Iovance Biotherapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:2LB vs ABCL, RCUS, VKTX: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Iovance Biotherapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Iovance Biotherapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Iovance Biotherapeutics's Shiller PE Ratio falls into.


FRA:2LB
34GF Score
Iovance Biotherapeutics Inc FRA:2LB
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Iovance Biotherapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Iovance Biotherapeutics's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Iovance Biotherapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.095/333.9520*333.9520
=-0.095

Current CPI (Jun. 2026) = 333.9520.

Iovance Biotherapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -1.025 241.428 -1.418
201612 -0.237 241.432 -0.328
201703 -0.309 243.801 -0.423
201706 -0.329 244.955 -0.449
201709 -0.294 246.819 -0.398
201712 -0.304 246.524 -0.412
201803 -0.251 249.554 -0.336
201806 -0.291 251.989 -0.386
201809 -0.309 252.439 -0.409
201812 -0.237 251.233 -0.315
201903 -0.266 254.202 -0.349
201906 -0.336 256.143 -0.438
201909 -0.363 256.759 -0.472
201912 -0.450 256.974 -0.585
202003 -0.498 258.115 -0.644
202006 -0.417 257.797 -0.540
202009 -0.340 260.280 -0.436
202012 -0.386 260.474 -0.495
202103 -0.428 264.877 -0.540
202106 -0.440 271.696 -0.541
202109 -0.468 274.310 -0.570
202112 -0.558 278.802 -0.668
202203 -0.527 287.504 -0.612
202206 -0.596 296.311 -0.672
202209 -0.636 296.808 -0.716
202212 -0.604 296.797 -0.680
202303 -0.467 301.836 -0.517
202306 -0.434 305.109 -0.475
202309 -0.431 307.789 -0.468
202312 -0.413 306.746 -0.450
202403 -0.386 312.332 -0.413
202406 -0.316 314.175 -0.336
202409 -0.252 315.301 -0.267
202412 -0.248 315.605 -0.262
202503 -0.333 319.799 -0.348
202506 -0.286 322.561 -0.296
202509 -0.213 324.800 -0.219
202512 -0.154 324.054 -0.159
202603 -0.164 330.213 -0.166
202606 -0.095 333.952 -0.095

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Iovance Biotherapeutics Business Description

Address 825 Industrial Road, Suite 100, San Carlos, CA, USA, 94070
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
34GF Score

Get the complete analysis for FRA:2LB

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.87
Price